Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). Meeting Abstract

cited authors

  • Agarwal, Neeraj; Shore, Neal D.; Dunshee, Curtis; Karsh, Lawrence Ivan; Sullivan, Beth; Di Santo, Nicola; Elmeliegy, Mohamed; Lin, Xun; Czibere, Akos Gabor; Fizazi, Karim

Publication Date

  • May 20, 2019

webpage

published in

category

volume

  • 37

issue

  • 15